Waters Corporation
WAT
$377.31
-0.79%
Waters Corporation is a leading provider of analytical instruments, including liquid chromatography, mass spectrometry, and thermal analysis tools, serving the healthcare, life sciences, and diagnostics industries. The company holds a strong competitive position as a specialized player in high-precision analytical technologies, with a reputation for innovation and reliability. In early 2026, Waters completed a transformative merger with BD's life science and diagnostics business, significantly expanding its diagnostics and discovery-related life science tools portfolio. The current investor narrative centers on the integration of this acquisition, its impact on revenue growth and margins, and the potential for accelerated earnings as the company leverages its expanded capabilities.…
WAT
Waters Corporation
$377.31
Investment Opinion: Should I buy WAT Today?
Rating: Buy. Thesis: Waters is a high-quality analytical instruments company undergoing a transformative acquisition that should drive revenue growth and margin expansion over the next 12-18 months, supported by a strong analyst consensus and reasonable forward valuation. The average analyst target of $413.13 implies 10.3% upside, and the consensus recommendation is Buy (mean 1.84).
Supporting Evidence: The Q1 2026 revenue growth of 91.48% YoY demonstrates the acquisition's immediate impact. The forward P/E of 22.72 is attractive relative to the trailing P/E of 35.17, implying expected earnings normalization. The company's historical operating margins above 28% (Q4 2025: 33.3%) suggest strong profitability potential post-integration. Free cash flow TTM of $264 million provides a cushion for integration costs. The P/S of 7.14, while above the industry average of ~4.5x, is justified by Waters' competitive position and growth prospects.
Risks & Conditions: The biggest risks are integration execution (margin recovery), potential revenue deceleration, and valuation compression. This Buy rating would be downgraded to Hold if gross margins fail to recover above 55% within two quarters or if revenue growth falls below 10% YoY. It would be upgraded to Strong Buy if the stock pulls back to the $340 level (near the low analyst target) while fundamentals remain intact. Overall, Waters appears fairly valued relative to its growth potential, with the forward P/E of 22.72 suggesting modest upside from current levels.
Sign up to view all
WAT 12-Month Price Forecast
The AI assessment is bullish on WAT with medium confidence, reflecting the strong revenue growth from the BD acquisition and reasonable forward valuation. The key factor is margin recovery: if gross margins can return to historical levels above 57%, the stock could re-rate significantly. However, the medium confidence reflects integration uncertainty and the elevated EV/EBITDA multiple. The stance would be upgraded to high confidence if Q2 2026 shows gross margins above 50% and positive free cash flow. It would be downgraded to neutral if margins remain below 48% or if revenue growth decelerates below 10%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Waters Corporation's 12-month outlook, with a consensus price target around $413.26 and implied upside of +9.5% versus the current price.
Average Target
$413.26
0 analysts
Implied Upside
+9.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$349 - $460
Analyst target range
Waters is covered by 24 analysts, with a consensus recommendation of 'Buy' (mean rating 1.84 on a 1-5 scale where 1 is Strong Buy). The average target price is $413.13, implying approximately 10.3% upside from the current price of $374.68. The distribution shows a bullish tilt, with 10 recent ratings including 4 Buys, 4 Holds, and 2 Neutrals, and no Sell ratings. The consensus reflects confidence in the acquisition strategy and long-term growth, though some analysts remain cautious on near-term integration risks. The target range spans from a low of $349.00 to a high of $460.00, representing a spread of 31.8% relative to the average. The high target of $460 implies 22.8% upside and likely assumes successful integration, margin recovery, and multiple expansion. The low target of $349 suggests 6.9% downside, pricing in execution risks or slower-than-expected synergies. The wide spread indicates high uncertainty around the acquisition's impact. Recent ratings have been stable, with no major upgrades or downgrades in the past two months, suggesting analysts are in a 'wait-and-see' mode. The absence of negative revisions supports a cautiously optimistic outlook.
Drowning in data?
Find the real signal!
Bulls vs Bears: WAT Investment Factors
Waters Corporation presents a compelling but high-conviction investment case centered on the transformative BD acquisition. On the bull side, the acquisition has dramatically boosted revenue (91.48% YoY growth in Q1 2026), the analyst consensus is bullish with 10.3% upside to the average target, and the forward P/E of 22.72 suggests reasonable valuation for expected earnings recovery. However, bearish concerns include significant near-term margin compression (gross margin down 12.8pp), elevated valuation multiples relative to peers, and integration uncertainty reflected in the wide analyst target spread. The single most important tension is whether the company can successfully integrate the BD assets to restore pre-acquisition margins (operating margin >28%) and generate sustainable free cash flow. If integration succeeds, the stock could re-rate higher; if not, the premium valuation could compress. Currently, the bull case has slightly stronger evidence given the strong revenue growth and analyst support, but execution risk remains high.
Bullish
- Transformative BD Acquisition Driving Growth: Q1 2026 revenue surged 91.48% YoY to $1.267 billion, primarily from the BD life science and diagnostics acquisition, expanding Waters' total addressable market and adding diagnostics revenue streams.
- Strong Analyst Consensus and Upside: With 24 analysts covering WAT, the consensus is Buy (mean rating 1.84) and the average target price of $413.13 implies 10.3% upside from the current $374.68, reflecting confidence in the acquisition strategy.
- Healthy Long-Term Profitability Metrics: Despite a Q1 net loss, trailing twelve-month ROE stands at 25.09% and operating margin historically above 28% (Q4 2025: 33.3%), indicating strong underlying profitability post-integration.
- Attractive Forward Valuation: The forward P/E of 22.72 is reasonable for a company with expected earnings recovery, and the P/S of 7.14, while above the industry average of ~4.5x, is justified by Waters' competitive moat and growth potential.
Bearish
- Acquisition-Related Earnings and Margin Pressure: Q1 2026 reported a net loss of -$72 million and gross margin compressed to 46.96% from 59.79% in Q4 2025, reflecting integration costs and lower-margin diagnostics revenue, which could persist.
- Elevated Valuation vs. Peers: Waters' EV/EBITDA of 23.23 is well above the industry average of ~18x, and the trailing P/E of 35.17 is near the high end of its 2-year range (22x-44x), leaving limited room for multiple expansion.
- High Uncertainty Around Integration: The wide analyst target spread ($349-$460) and the absence of recent rating changes indicate significant uncertainty about the acquisition's impact on revenue growth and margins.
- Negative Free Cash Flow in Recent Quarter: Q1 2026 free cash flow was -$42 million due to integration costs, and while TTM FCF is $264 million, the near-term cash flow strain could limit financial flexibility.
WAT Technical Analysis
Waters is in a broad uptrend over the past year, with a 1-year price change of +25.53%, significantly outperforming the S&P 500's +16.47%. The current price of $374.68 sits at 60.3% of its 52-week range ($275.05 to $414.15), indicating the stock is in the middle of its range after recovering from a sharp pullback earlier in the year. This positioning suggests the stock has room to run toward the highs but is not yet overextended, offering a balanced risk-reward profile. Short-term momentum is positive, with a 1-month change of +1.49% and a 3-month change of +20.92%, the latter showing strong acceleration from the March lows near $283. The 3-month rally contrasts with a 6-month decline of -4.49%, indicating a V-shaped recovery from the February-March selloff. This divergence suggests the stock may be in the early stages of a new uptrend, though the 1-month gain is modest, hinting at consolidation after the sharp 3-month move. The 52-week low of $275.05 provides strong support, while the 52-week high of $414.15 is the key resistance. A breakout above $414 would signal a resumption of the long-term uptrend, while a breakdown below $275 would be a bearish signal. The stock's beta of 1.202 indicates it is 20% more volatile than the market, meaning it amplifies market moves—a factor for risk management.
Beta
1.20
1.20x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$275-$414
Price range past year
Annual Return
+30.7%
Cumulative gain past year
| Period | WAT Return | S&P 500 |
|---|---|---|
| 1m | -0.2% | +0.2% |
| 3m | +22.9% | +3.7% |
| 6m | +1.8% | +8.0% |
| 1y | +30.7% | +18.2% |
| ytd | -1.2% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WAT Fundamental Analysis
Waters' revenue trajectory has been volatile, with the most recent quarter (Q1 2026) reporting revenue of $1.267 billion, a staggering 91.48% YoY growth, largely due to the BD acquisition. However, excluding the acquisition, organic growth was likely modest, as prior quarters showed steady but slower expansion: Q4 2025 revenue was $932 million, Q3 2025 was $800 million, and Q2 2025 was $771 million. The acquisition has dramatically boosted top-line scale, but the sustainability of growth depends on integration and cross-selling. Revenue segments show Waters Instrument Systems ($355M) and Chemistry Consumables ($170M) as key drivers, while the acquired diagnostics business adds new revenue streams. Profitability has been mixed: Q1 2026 reported a net loss of -$72 million (net margin -5.68%) due to acquisition-related costs, compared to a net income of $225 million in Q4 2025 (net margin 24.16%). Gross margin compressed to 46.96% in Q1 2026 from 59.79% in Q4 2025, likely reflecting lower-margin diagnostics revenue. Excluding the acquisition, the company has historically maintained strong margins, with operating margins above 28% in recent quarters. The balance sheet shows a debt-to-equity ratio of 0.58, manageable leverage, and a current ratio of 1.73, indicating adequate liquidity. Free cash flow was negative -$42 million in Q1 2026 due to integration costs, but trailing twelve-month FCF is $264 million. ROE stands at 25.09%, reflecting solid returns on equity despite the recent loss. The company's financial health is stable, but the acquisition has temporarily pressured cash flows and margins.
Quarterly Revenue
$1.3B
2026-04
Revenue YoY Growth
+91.5%
YoY Comparison
Gross Margin
47.0%
Latest Quarter
Free Cash Flow
$263999000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WAT Overvalued?
Since net income is negative in the most recent quarter, the trailing P/E ratio of 35.17 is not meaningful; instead, we lead with the price-to-sales (P/S) ratio of 7.14. The forward P/E of 22.72 is more relevant, implying the market expects earnings to normalize post-acquisition. The gap between the trailing P/E (35.17) and forward P/E (22.72) suggests the market anticipates significant earnings recovery, which is typical for a company undergoing a transformative acquisition. Compared to the industry (Medical - Diagnostics & Research), Waters' P/S of 7.14 is above the sector average of approximately 4.5x (based on typical healthcare tools peers), representing a 59% premium. This premium is justified by Waters' strong competitive position, high gross margins (57.8% trailing), and the growth potential from the BD acquisition. However, the EV/EBITDA of 23.23 is also elevated relative to the industry average of ~18x, indicating the market is pricing in margin expansion. Historically, Waters' trailing P/E has ranged from 22x to 44x over the past two years, with the current 35.17x near the higher end of that band. The P/S ratio of 7.14 is below the historical peak of 33x in 2021, suggesting the stock is not at extreme valuation levels. The current valuation implies the market is optimistic about the acquisition's benefits but not overly exuberant, leaving room for upside if integration succeeds.
PE
35.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 22x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Waters faces significant financial risks from the BD acquisition, including a Q1 2026 net loss of -$72 million and negative free cash flow of -$42 million. Gross margin compressed to 46.96% from 59.79% in Q4 2025, indicating lower-margin revenue mix. The debt-to-equity ratio of 0.58 is manageable, but the company's ability to service debt depends on margin recovery. Revenue concentration is also a risk, as the acquired diagnostics business now represents a large portion of sales, and any slowdown in that segment could impact overall growth.
Market & Competitive Risks: Waters' valuation is elevated relative to peers, with an EV/EBITDA of 23.23 versus the industry average of ~18x, making it vulnerable to multiple compression if growth disappoints. The stock's beta of 1.202 implies higher sensitivity to market downturns, and the 6-month price decline of -4.49% (vs. S&P 500 +7.21%) already reflects some macro headwinds. Competitive risks include potential share loss in chromatography/mass spectrometry to larger players like Thermo Fisher or Agilent, though Waters' niche focus provides some insulation.
Worst-Case Scenario: If integration fails to deliver expected synergies, margins remain depressed, and revenue growth decelerates, the stock could fall to its 52-week low of $275.05, representing a 26.6% decline from the current price of $374.68. In a severe recession, the stock could test the March 2026 low of $283.32, a 24.4% drop. The maximum drawdown over the past year was -31.32%, suggesting a potential loss of up to 31% from current levels in an adverse scenario.
FAQ
The key risks are: 1) Integration execution risk—the BD acquisition could fail to deliver expected synergies, as evidenced by the Q1 2026 net loss of -$72 million and gross margin compression to 46.96%. 2) Valuation risk—the EV/EBITDA of 23.23 is above the industry average, making the stock vulnerable to multiple compression if growth disappoints. 3) Macro risk—with a beta of 1.202, WAT is more sensitive to market downturns, and a recession could reduce capital equipment spending. 4) Competitive risk—larger players like Thermo Fisher could gain share in chromatography/mass spectrometry. The most severe risk is integration failure, which could drive the stock to the 52-week low of $275.05, a 26.6% decline from current levels.
The 12-month forecast for WAT is cautiously bullish, with three scenarios: Bull case (30% probability) targets $413-$460, assuming successful integration and margin recovery, driven by catalysts like Q2 margin improvement and cost synergy announcements. Base case (50% probability) targets $375-$413, with gradual margin improvement and steady growth. Bear case (20% probability) targets $275-$349, assuming integration challenges and potential recession. The most likely scenario is the base case, where the stock trades near the analyst average target of $413.13, implying 10.3% upside. The key assumption is that gross margins recover to at least 55% by year-end, enabling earnings growth to support the forward P/E of 22.72.
WAT appears fairly valued to slightly overvalued based on current metrics. The trailing P/E of 35.17 is elevated due to depressed earnings from acquisition costs, but the forward P/E of 22.72 is more reasonable and in line with historical averages. The P/S of 7.14 is above the industry average of ~4.5x, indicating a premium for Waters' competitive position and growth potential. The EV/EBITDA of 23.23 is also above the peer average of ~18x, suggesting the market is pricing in margin expansion. Compared to its own history, the trailing P/E is near the high end of the 2-year range (22x-44x), while the P/S is below the 2021 peak of 33x. Overall, the valuation implies the market expects successful integration and margin recovery, but leaves limited room for error.
WAT appears to be a good buy for investors with a 12-18 month horizon who are comfortable with near-term integration risk. The stock offers 10.3% upside to the average analyst target of $413.13, supported by a consensus Buy rating. The forward P/E of 22.72 is reasonable given expected earnings recovery, and the company's strong competitive position in analytical instruments provides a moat. However, the stock is not without risk: the Q1 2026 net loss and margin compression highlight integration challenges. For long-term investors, the acquisition could create significant value, but near-term volatility is likely. It is a good buy for those who believe management can execute the integration successfully and restore margins.
WAT is better suited for medium- to long-term investment (12-24 months) due to the transformative acquisition that will take time to fully integrate and realize synergies. The stock's beta of 1.202 indicates higher volatility, making it less suitable for short-term trading unless one can tolerate sharp swings. The company does not pay a dividend (yield 0%), so total return depends on price appreciation. For long-term investors, the expanded diagnostics portfolio and strong competitive position in analytical instruments provide a growth runway. A minimum holding period of 12 months is recommended to allow the integration benefits to materialize. Short-term traders may find opportunities around earnings announcements, but the wide analyst target spread ($349-$460) suggests high uncertainty.